| Literature DB >> 36065259 |
Haider Ali Malakzai1, Ahmed Maseh Haidary1, Saleema Gulzar2, Mujtaba Haidari1, Abdul Sami Ibrahimkhil3, Ramin Saadaat1, Ahmadullah Hakimi1, Sayed Murtaza Sadat Hofiani4, Soma Rahmani5, Jamshid Abdul-Ghafar1.
Abstract
Purpose: Cancer is one of the leading causes of mortality and morbidity, and therefore, tremendous research work is continuously being done around the world with consideration of etiopathogenesis as well as identification of therapeutic targets. Decades of continuous war in Afghanistan has left the medical infrastructure of the country in a miserable situation. There is a serious deficiency in research work in the fields of pathology and oncology at the moment with minimal data available to elaborate about the demographic characteristics of various malignant disorders in the country, which would be indispensable to pave the way for further research and development. Patients andEntities:
Keywords: Afghanistan; cancer; lymphoma; prevalence; sarcoma
Year: 2022 PMID: 36065259 PMCID: PMC9440704 DOI: 10.2147/CMAR.S377710
Source DB: PubMed Journal: Cancer Manag Res ISSN: 1179-1322 Impact factor: 3.602
Frequently Involved Primary Sites of Malignant Tumors in Both Genders (n=2183)
| S. No# | Primary Site | Female (n=1094) | Male (n=1089) | Total (n=2183) | |||
|---|---|---|---|---|---|---|---|
| Cases | % | Cases | % | Cases | % | ||
| 1 | Breast | 323 | 29.5% | – | – | 323 | 14.8% |
| 2 | Esophagus | 107 | 9.8% | 178 | 16.3% | 285 | 13.1% |
| 3 | Skin | 85 | 7.8% | 152 | 14.0% | 237 | 10.9% |
| 4 | Bone and soft tissue | 72 | 6.6% | 97 | 8.9% | 169 | 7.7% |
| 5 | Colorectum | 68 | 6.2% | 96 | 8.8% | 164 | 7.5% |
| 6 | Urinary bladder | 28 | 2.6% | 61 | 5.6% | 89 | 4.1% |
| 7 | NHL extranodal | 32 | 2.9% | 44 | 4.0% | 76 | 3.5% |
| 8 | Lymph node (NHL) | 29 | 2.7% | 46 | 4.2% | 75 | 3.4% |
| 9 | Stomach | 23 | 2.1% | 50 | 4.6% | 73 | 3.3% |
| 10 | Testis | – | – | 59 | 5.4% | 59 | 2.7% |
| 11 | Gastroesophageal junction | 12 | 1.1% | 46 | 4.2% | 58 | 2.7% |
| 12 | Ovary | 58 | 5.3% | – | – | 58 | 2.7% |
| 13 | Kidney | 21 | 1.9% | 36 | 3.3% | 57 | 2.6% |
| 14 | Prostate | – | – | 49 | 4.5% | 49 | 2.2% |
| 15 | Uterine body | 47 | 4.3% | – | – | 47 | 2.2% |
| 16 | Uterine cervix | 44 | 4.0% | – | – | 44 | 2.0% |
| 17 | Lymph node (HL) | 12 | 1.1% | 29 | 2.7% | 41 | 1.9% |
| 18 | Eye | 17 | 1.6% | 22 | 2.0% | 39 | 1.8% |
| 19 | Central nervous system | 14 | 1.3% | 20 | 1.8% | 34 | 1.6% |
| 20 | Gallbladder | 24 | 2.2% | 9 | 0.8% | 33 | 1.5% |
| 21 | Miscellaneous | 78 | 7.1% | 95 | 8.7% | 173 | 7.9% |
Abbreviations: NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma.
Decade-Wise Age Distribution of Common Primary Malignant Tumors in Females (n=1094)
| Serial No. # | Primary Site | Age Range in Years | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0–10 | 11–20 | 21–30 | 31–40 | 41–50 | 51–60 | 61–70 | >70 | Total | ||
| 1 | Breast | – | – | 34 (31.2%) | 93 (47.4%) | 88 (36.7%) | 60 (27.5%) | 35 (21.2%) | 13 (18.3%) | 323 (29.5%) |
| 2 | Esophagus | – | – | 2 (1.8%) | 8 (4.1%) | 26 (10.8%) | 34 (15.6%) | 27 (16.4%) | 10 (14.1%) | 107 (9.8%) |
| 3 | Skin | 1 (2.1%) | 2 (4.2%) | 6 (5.5%) | 16 (8.2%) | 10 (4.2%) | 18 (8.3%) | 15 (9.1%) | 17 (23.9%) | 85 (7.8%) |
| 4 | Bone and soft tissue | 6 (12.8%) | 22 (45.8%) | 15 (13.8%) | 5 (2.6%) | 9 (3.8%) | 7 (3.2%) | 8 (4.2%) | – | 72 (6.6%) |
| 5 | Colorectum | – | 1 (2.1%) | 4 (3.7%) | 9 (4.6%) | 10 (4.2%) | 22 (10.1%) | 12 (7.3%) | 10 (14.1%) | 68 (2.6%) |
| 6 | Ovary | 4 (8.5%) | 4 (8.3%) | 14 (12.8%) | 12 (6.1%) | 16 (6.7%) | 6 (2.8%) | 2 (1.2%) | – | 58 (5.3%) |
| 7 | Uterine body | – | 1 (2.1%) | 5 (4.6%) | 10 (5.1%) | 13 (5.4%) | 8 (3.7%) | 9 (5.5%) | 1 (1.4%) | 47 (4.3%) |
| 8 | Uterine cervix | – | – | – | 7 (3.6%) | 15 (6.3%) | 10 (4.6%) | 11 (6.7%) | 1 (1.4%) | 44 (4.0%) |
| 9 | NHL extranodal | 10 (21.3%) | 4 (8.3%) | 2 (1.8%) | 2 (1.0%) | 8 (3.3%) | 2 (0.9%) | 4 (2.4%) | – | 32 (2.9%) |
| 10 | Lymph node (NHL) | 2 (4.3%) | 3 (6.3%) | 7 (6.4%) | 5 (2.6%) | 6 (2.5%) | 0 | 5 (3.0%) | 1 (1.4%) | 29 (2.7%) |
| 11 | Miscellaneous | 24 (51.1%) | 11 (22.9%) | 20 (18.3%) | 29 (14.8%) | 39 (16.3%) | 51 (23.4%) | 37 (22.4%) | 18 (25.4%) | 229 (20.9%) |
| Total | 47 (100%) | 48 (100%) | 109 (100%) | 196 (100%) | 240 (100%) | 218 (100%) | 165 (100%) | 71 (100%) | 1094 (100%) | |
Abbreviation: NHL, non-Hodgkin lymphoma.
Decade-Wise Age Distribution of Common Primary Malignant Tumors in Males (n=1089)
| Serial No. # | Primary Site | Age Range in Years | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0–10 | 11–20 | 21–30 | 31–40 | 41–50 | 51–60 | 61–70 | >70 | Total | ||||
| 1 | Esophagus | – | – | 1 1.1%) | 6 (5.8%) | 31 (19.6%) | 53 (24.9%) | 55 (22.6%) | 32 (20.1%) | 178 (16.3%) | ||
| 2 | Skin | – | 1 (1.8%) | 3 (3.4%) | 15 (14.4%) | 26 16.5%) | 30 (14.1%) | 39 (16.0%) | 38 (23.9%) | 152 (14.0%) | ||
| 3 | Bone and soft tissue | 9 (13.0%) | 27 (48.2%) | 19 (21.8%) | 15 (14.4%) | 8 (5.1%) | 9 (4.2%) | 5 (2.1%) | 5 (3.1%) | 97 (8.9%) | ||
| 4 | Colorectum | 1 (1.4%) | 1 (1.8%) | 11 (12.6%) | 15 (14.4%) | 8 (5.1%) | 20 (9.4%) | 27 (11.1%) | 13 (8.2%) | 96 (8.8%) | ||
| 5 | Urinary bladder | 3 (4.3%) | – | 5 (5.7%) | 2 (1.9%) | 9 (5.7%) | 20 (9.4%) | 15 (6.2%) | 7 (4.4%) | 61 (5.6%) | ||
| 6 | Testis | 15 (21.7%) | – | 23 (26.4%) | 15 (14.4%) | 4 (2.5%) | 2 (0.9%) | – | – | 59 (5.4%) | ||
| 7 | Stomach | – | – | 1 (1.1%) | 5 (4.8%) | 8 (5.1%) | 10 (4.7%) | 16 (6.6%) | 10 (6.3%) | 50 (4.6%) | ||
| 8 | Prostate | – | – | – | 2 (1.9%) | 2 (1.3%) | 7 (3.3%) | 21 (8.6%) | 17 (10.7%) | 49 (4.5%) | ||
| 9 | Gastroesophageal junction | – | – | 1 (1.1%) | – | 1 (0.6%) | 12 (5.6%) | 14 (5.8%) | 18 (11.3%) | 46 (4.2%) | ||
| 10 | Lymph node (NHL) | 3 (4.3%) | 3 (5.4%) | 6 (6.9%) | 2 (1.9%) | 8 (5.1%) | 11 (5.2%) | 13 (5.3%) | – | 46 (4.2%) | ||
| 11 | Miscellaneous | 38 (55.1%) | 24 (42.9%) | 17 (19.5%) | 27 (26.0%) | 53 (33.5%) | 39 (18.3%) | 38 (15.6%) | 19 (11.9%) | 255 (23.4%) | ||
| 69 (100%) | 56 (100%) | 87 (100%) | 104 (100%) | 158 (100%) | 213 (100%) | 243 (100%) | 159 (100%) | 1089 (100%) | ||||
Abbreviation: NHL, non-Hodgkin lymphoma.
Figure 1Histologic types of malignant breast tumors in females (n=323).
Figure 2Histologic grades of invasive mammary carcinomas of female breast (n=292).
Figure 3Histologic types of esophageal carcinoma in both genders (n=285).
Figure 4Histologic types of malignant skin tumors in both genders (n=237).
Figure 5Histologic types of malignant bone and soft tissue tumors in both genders (n=169).
Figure 6Histologic types of malignant CNS tumors in both genders (n=34).
Figure 7Sites involved by extranodal non-Hodgkin lymphoma in both genders (n=30).
Figure 8Stages of primary malignant tumors in both genders (n=357).
Common Malignant Tumor Types with Primary Sites and Laterality (n=366)
| Serial. No. # | Primary Site | Tumor Type | Tumor Laterality | Total | ||
|---|---|---|---|---|---|---|
| Bilateral | Left | Right | ||||
| 1 | Breast | Invasive Ductal Carcinoma | 2 (0.7%) | 146 (51.4%) | 136 (47.9%) | 284 (100%) |
| 2 | Kidney | Renal Cell Carcinoma | – | 21 (63.6%) | 12 (36.4) | 33 (100%) |
| 3 | Testis | Seminoma | – | 9 (40.9%) | 13 (59.1%) | 22 (100%) |
| 4 | Ovary | Serous Cystadenocarcinoma | 3 (20.0%) | 8 (53.3%) | 4 (26.7%) | 15 (100%) |
| 5 | Eye | Retinoblastoma | – | 6 (50%) | 6 (50%) | 12 (100%) |
Figure 9Common biopsy techniques for sampling primary malignant tumors (n=2183).